Cna Financial Corp Intellia Therapeutics, Inc. Transaction History

Cna Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$53.92 - $71.7 $112,692 - $149,853	-2,090 Reduced 24.3%	6,510 $364,000
Q2 2022 Aug 09, 2022	SELL	$38.49 - $76.21 $15,011 - $29,721	-390 Reduced 4.34%	8,600 $445,000
Q1 2022 May 10, 2022	BUY	$58.27 - $118.99 $62,931 - $128,509	1,080 Added 13.65%	8,990 $653,000
Q4 2021 Feb 11, 2022	BUY	$100.76 - $138.36 $88,668 - $121,756	880 Added 12.52%	7,910 $935,000
Q3 2021 Nov 12, 2021	BUY	$132.37 - $176.78 $37,063 - $49,498	280 Added 4.15%	7,030 $943,000
Q2 2021 Aug 12, 2021	SELL	$60.88 - $161.91 $233,170 - $620,115	-3,830 Reduced 36.2%	6,750 $1.09 Million
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $492,922 - $885,334	10,580 New	10,580 $849,000

344

98.4M

784K

713K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $734M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.